Gilead Sciences (GILD) Non-Current Debt (2010 - 2026)

Gilead Sciences has reported Non-Current Debt for 17 years, with the latest figure at $20.9 billion in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt fell 5.8% year-over-year to $20.9 billion; the trailing twelve-month figure through Mar 2026 stood at $20.9 billion (down 5.8% YoY), and the FY2025 full-year result was $22.1 billion, down 11.11% from the prior year.
• Non-Current Debt for Q1 2026 stood at $20.9 billion, down from $22.1 billion in the prior quarter.
• The five-year high for Non-Current Debt was $25.2 billion in Q2 2022, with the low at $20.9 billion in Q1 2026.
• Historically, Non-Current Debt has averaged $22.7 billion across 5 years, with a median of $22.1 billion in 2025.
• Annual changes were most pronounced in 2023 — Non-Current Debt retreated 15.82% — and 2024, when it advanced 7.36%.
• Gilead Sciences' Non-Current Debt stood at $23.0 billion in 2022, then climbed by 1.01% to $23.2 billion in 2023, then gained by 7.36% to $24.9 billion in 2024, then decreased by 11.11% to $22.1 billion in 2025, then retreated by 5.73% to $20.9 billion in 2026.
• The last three Non-Current Debt figures came in at $20.9 billion (Q1 2026), $22.1 billion (Q4 2025), and $22.1 billion (Q3 2025), per Business Quant data.